Glycopyrronium tosylate explained

Jan:	Glycopyrronium tosilate hydrate
Tradename:	Qbrexza, Rapifort
Dailymedid:	Glycopyrronium
Routes Of Administration:	Topical
Class:	Muscarinic antagonist
Atc Prefix:	D11
Atc Suffix:	AA01
Legal Us:	Rx-only
Legal Us Comment:	^[1]
Legal Status:	Rx-only
Cas Number:	1624259-25-1
Pubchem:	121225724
Drugbank:	DBSALT002800
Chemspiderid:	58902513
Unii:	1PVF6JLU7B
Kegg:	D10939
Chembl:	3707243
Smiles:	O.Cc1ccc(cc1)S(=O)(=O)[O-].C[N+]2(C)CC[C@@H](C2)OC(=O)[C@@](O)(C3CCCC3)c4ccccc4
Stdinchi:	1S/C19H28NO3.C7H8O3S.H2O/c1-20(2)13-12-17(14-20)23-18(21)19(22,16-10-6-7-11-16)15-8-4-3-5-9-15;1-6-2-4-7(5-3-6)11(8,9)10;/h3-5,8-9,16-17,22H,6-7,10-14H2,1-2H3;2-5H,1H3,(H,8,9,10);1H2/q+1;;/p-1/t17-,19-;;/m0../s1
Stdinchikey:	UOWOLENSDISMPG-FFUVTKDNSA-M

Glycopyrronium tosylate, sold under the brand name Qbrexza among others, is a medication used for the treatment of primary axillary hyperhidrosis.^[2] ^[3]

It was approved for medical use in the United States in June 2018,^[4] and in Japan in January 2022.^[5]

Notes and References

Web site: Qbrexza- glycopyrronium cloth . DailyMed . 17 January 2022 . 2 November 2022.
Nwannunu CE, Limmer AL, Coleman K, Shah R, Patel RR, Mui UN, Tyring SK . Glycopyrronium Tosylate (Qbrexza) for Hyperhidrosis . Skin Therapy Letter . 24 . 2 . 1–3 . March 2019 . 30970203 .
Lamb YN . Topical Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis: A Profile of Its Use . Clinical Drug Investigation . 39 . 11 . 1141–1147 . November 2019 . 31571127 . 6877702 . 10.1007/s40261-019-00853-x .
Web site: Drug Approval Package: Qbrexza (glycopyrronium) . U.S. Food and Drug Administration (FDA) . 20 November 2018 . 1 November 2022.
Web site: Maruho Launches Primary Axillary Hyperhidrosis Treatment . Maruho . 23 May 2022 . 2 November 2022.